555 related articles for article (PubMed ID: 9233866)
1. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer.
Bolla M
Eur Urol; 1999; 35 Suppl 1():23-5; discussion 26. PubMed ID: 10081699
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
[TBL] [Abstract][Full Text] [Related]
4. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
Lawton CA; Winter K; Grignon D; Pilepich MV
J Clin Oncol; 2005 Feb; 23(4):800-7. PubMed ID: 15681524
[TBL] [Abstract][Full Text] [Related]
5. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
6. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
Bolla M; Van Tienhoven G; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Billiet I; Torecilla JL; Pfeffer R; Cutajar CL; Van der Kwast T; Collette L
Lancet Oncol; 2010 Nov; 11(11):1066-73. PubMed ID: 20933466
[TBL] [Abstract][Full Text] [Related]
7. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
[TBL] [Abstract][Full Text] [Related]
8. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
[TBL] [Abstract][Full Text] [Related]
9. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
Messing EM; Manola J; Sarosdy M; Wilding G; Crawford ED; Trump D
N Engl J Med; 1999 Dec; 341(24):1781-8. PubMed ID: 10588962
[TBL] [Abstract][Full Text] [Related]
10. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
11. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
12. Duration of androgen suppression in the treatment of prostate cancer.
Bolla M; de Reijke TM; Van Tienhoven G; Van den Bergh AC; Oddens J; Poortmans PM; Gez E; Kil P; Akdas A; Soete G; Kariakine O; van der Steen-Banasik EM; Musat E; Piérart M; Mauer ME; Collette L;
N Engl J Med; 2009 Jun; 360(24):2516-27. PubMed ID: 19516032
[TBL] [Abstract][Full Text] [Related]
13. Goserelin and locally advanced prostate cancer: new indication. Pros and cons.
Prescrire Int; 2000 Jun; 9(47):75-6. PubMed ID: 11010743
[TBL] [Abstract][Full Text] [Related]
14. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.
Anscher MS; Clough R; Robertson CN; Prosnitz LR; Dahm P; Walther P; Donatucci CF; Albala DM; Febbo P; George DJ; Sun L; Moul JW
Prostate Cancer Prostatic Dis; 2006; 9(3):254-60. PubMed ID: 16880828
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer--the therapeutic challenge of locally advanced disease.
Blasko JC; Lange PH
N Engl J Med; 1997 Jul; 337(5):340-1. PubMed ID: 9233872
[No Abstract] [Full Text] [Related]
16. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209
[TBL] [Abstract][Full Text] [Related]
17. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
[TBL] [Abstract][Full Text] [Related]
18. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
19. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma.
Pickles T; Agranovich A; Berthelet E; Duncan GG; Keyes M; Kwan W; McKenzie MR; Morris WJ;
Cancer; 2002 Jan; 94(2):362-7. PubMed ID: 11900222
[TBL] [Abstract][Full Text] [Related]
20. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.
Bolla M; Collette L; Blank L; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Mattelaer J; Lopez Torecilla J; Pfeffer JR; Lino Cutajar C; Zurlo A; Pierart M
Lancet; 2002 Jul; 360(9327):103-6. PubMed ID: 12126818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
